PAOG "SCREAMS" BUY - CBD Pharmaceutical Prospect And Cannabis Legalization Prospects

January 7, 2021 -- InvestorsHub NewsWire -- via pennymillions -- Amercian Bulls (americanbulls.com/PAOG) rated PAOG Group, Inc. (USOTC: PAOG) a 'SCREAMING" BUY today:

"The green light is on and this security is now screaming BUY. It is action time! The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. Do not miss this bullish opportunity."

PAOG announced a CRO contract with Veristat earlier this week to develop a CBD Pharmaceutical Treamtent for COPD:

"PAOG today [Tuesday, Jan 5th] announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough, Massachusetts. PAOG has engaged Veristat to assist in advancing PAOG with its proprietary Cannabidiol (CBD) extract for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) toward initiating an Investigational New Drug application (IND) with the Food and Drug Administration (FDA)."

'On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."

"Coupled with Joe Biden’s presidential win, the new situation on Capitol Hill means that federal cannabis policy change is in the cards for the 117th Congress."

This is a quoute from an article addressing the Democratic Party Senate Win. See the rest of the article to get an idea of legalization opportunities for cannabis: